Breaking News
Get 40% Off 0
Is NVDA a 🟢 buy or 🔴 sell? Unlock Now

YS Biopharma challenges shareholder meeting validity

Published Feb 12, 2024 10:22AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters.
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio

GAITHERSBURG, Md. - YS Biopharma Co., Ltd. (NASDAQ: YS), a biopharmaceutical company, has raised questions about the validity of an extraordinary general meeting (EGM) convened by a group of its shareholders. The company asserts that the notice for the EGM, which aims to remove six of its seven directors, does not comply with the necessary procedural requirements.

On Monday, YS Biopharma issued a statement in response to a notice served by shareholders, including Mr. Yi Zhang and several investment companies, to hold an EGM on February 16, 2024, in Seattle, Washington. The company contends that the meeting has been improperly called, citing several reasons.

Firstly, YS Biopharma argues that the notice served on February 8, 2024, fails to meet the seven calendar days' notice required by the company's articles of association. Additionally, the directors proposed for removal were not given the required ten-day notice.

The company also highlighted discrepancies in the record date share count. The notice, according to YS Biopharma, incorrectly states the number of ordinary shares issued and outstanding as of February 8, 2024. YS Biopharma had issued additional shares to an institutional investor on February 7, 2024, following a $40 million private placement transaction announced on February 9, 2024. Consequently, the actual number of shares issued and outstanding at the close of business on the record date was significantly higher than the number cited in the notice.

The company, which specializes in developing vaccines and therapeutic biologics for infectious diseases and cancer, is known for its proprietary PIKA® immunomodulating technology platform. YS Biopharma operates globally, with a presence in China, the United States, Singapore, and the Philippines.

This information is based on a press release statement from YS Biopharma Co., Ltd.

InvestingPro Insights

In light of YS Biopharma's recent challenges surrounding its extraordinary general meeting (EGM), it's important for investors to consider the company's financial health and market performance. According to real-time data from InvestingPro, YS Biopharma has a market capitalization of 38.99 million USD, reflecting its size within the biopharmaceutical industry. Despite an impressive gross profit margin of 80.05% over the last twelve months as of Q2 2024, the company is grappling with significant financial headwinds. The revenue growth during the same period shows a decline of 11.42%, and an even more concerning quarterly revenue decline of 50.11% in Q2 2024.

These financial metrics are crucial for shareholders to consider, especially in the context of the EGM and the company's future direction. An InvestingPro Tip underscores the company's heavy debt burden, which could be exacerbated by its difficulties in generating sufficient revenue to cover interest payments. Additionally, analysts do not anticipate YS Biopharma will be profitable this year, which may influence investor sentiment and the outcome of any corporate governance changes proposed at the EGM.

For investors seeking a more comprehensive analysis, there are additional InvestingPro Tips available that could provide deeper insights into YS Biopharma's valuation and future expectations. To explore these tips and enhance your investment strategy, visit and use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

YS Biopharma challenges shareholder meeting validity

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your profile, will be public on and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
Sign up with Email